LYON, France--(BUSINESS WIRE)--
Regulatory News:
(EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, announced that it will host a virtual KOL (Key Opinion Leader) event on including efficacy and safety results for its lead drug candidate, MaaT013, currently in development for acute Graft-versus-Host Disease (aGvHD) and details on MaaT033, developed as an adjuvant therapy to improve patients’ survival following allogeneic hematopoietic stem cell transplantation (allo-HSCT), on Monday, December 18, 2023, at 6:00 pm CET (12:00 pm EST).
The event will feature presentations from the Company’s CEO and co-founder, Hervé Affagard as well as the following KOLs:
- Mohamad Mohty, M.D., Ph.D., Professor of Hematology at Sorbonne University, and head of the Clinical Hematology and Cellular Therapy Department at Saint-Antoine Hospital, Paris, France will comment on the positive data on MaaT013 presented for the Early Access Program; and
- Florent Malard, M.D., Ph.D., Professor of Hematology at the Saint-Antoine Hospital and Sorbonne University, Principal investigator of Phase 2b trial evaluating MaaT033 in patients receiving allo-HSCT, will provide detailed information on the ongoing trial.
Virtual KOL Event Details
- Date & time: Monday, December 18, 2023, at 6:00 pm CET (12:00 pm EST).
- Registration & link to access the event:
- A replay will be made available on the Company’s for at least 90 days.
---
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma launched, in March 2022, an open-label, single arm, phase 3 clinical trial in patients with acute GvHD (aGvHD), following the achievement of its proof of concept in a phase 2 trial. Its powerful discovery and analysis platform, gutPrint®, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).
Forward-looking Statements
All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim”, “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.
View source version on businesswire.com:
